» LEARN MORE ABOUT COVID-19 VACCINES, TESTING, VISITOR & SAFETY REQUIREMENTS

MyHealth

Manage your account, request prescriptions, set up appointments & more.

LOG IN
Don't have an account
Contact Us
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label
    • see more mega-menu-label

Current Projects

Project Title: IOP-Related Force and Failure in the Optic Nerve Head

Sponsor: National Institutes of Health, National Eye Institute
Principal Investigator: Claude F. Burgoyne, MD From/To:  2017 - 2021 (yrs 20-23)

Project Narrative:

The principal goal of this proposal is to identify important molecular and cellular components of optic nerve head (ONH) connective tissue and retrolaminar myelin remodeling in monkey early experimental glaucoma (EG). To do so we will employ: state of the art quantitative mass spectroscopy, quantitative ONH immunohistochemistry and electron microscopy, and precise anatomic colocalization of all microscopic findings to in vivo optical coherence tomography (OCT). All outcomes will be reported in anatomically consistent, 30º degree ONH sectors that are oriented relative to the axis between the fovea and Bruch’s membrane opening. The results of these studies will allow us to identify age-related differences in connective tissue and myelin remodeling in monkey early EG and provide unprecedented microscopic support for their early, in vivo, detection by OCT.

Project Title: Optic Nerve Head Optical Coherence Tomography Imaging in Glaucoma

Sponsor: National Institutes of Health, National Eye Institute
Principal Investigator: Claude F. Burgoyne, MD From/To:  2014- 2018 (yrs 5-8)
Project Narrative: 
The principal goal of this study is to construct an Optical Coherence Tomography (OCT) phenotyping strategy for the optic nerve head (ONH), peripapillary retinal nerve fiber layer (RNFL) and macula tissues that improves the detection of glaucomatous damage and its progression. Aims 1 and 2 use OCT phenotyping to characterize age-related and glaucomatous structural change in monkeys so as to improve their clinical detection in humans (Aims 3 and 4). Expected outcomes include: improved detection of glaucoma onset and progression; confirmation that OCT ONH onset and progression predict subsequent RNFL and macula thickness loss; abandonment of clinician cup/disc ratio as the gold standard for clinical disc examination and its replacement with OCT anatomy and geometry; and adoption of OCT phenotyping by all subspecialties of Ophthalmology and Neurology that image the ONH, RNFL and macula tissues. 

Project Title: Spectralis Optical Coherence Tomography Imaging in Glaucoma

Sponsor: Heidelberg Engineering, Heidelberg, Germany
Principal Investigator: Claude F. Burgoyne, MD From/To:  2007 - present
Project Narrative:
This ongoing award provides unrestricted research funds and equipment to support the Specific Aims of both of the NIH R01 awards listed above. Dr. Burgoyne is a consultant to Heidelberg Engineering and receives occasional travel support for meetings, but holds no patents and earns no personal income from this relationship.